Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
Key players in the global autoimmune and inflammatory immunomodulators market: AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, and Pfizer. Other prominent vendors in the market are: AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, and UCB.
One of latest trends in the market is emergence of oral agents likely to improve patient outcomes. The advent of oral agents in the treatment of rheumatoid arthritis and IBD are expected to have a positive impact on the market growth. For instance, JAK inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug
Purchase a Copy of the Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=753899
The report, Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One of the primary drivers in the market is strong adoption of TNF-alpha inhibitors and B-cell inhibitors. The physicians prefer to adopt TNF-alpha inhibitors and B-cell inhibitors, owing to their established clinical profiles. For instance, AbbVie’s Humira, targeted at autoimmune and other inflammatory indications, reported a worldwide revenue of approximately $14 billion in 2015, indicating an approximate growth of 12% year-on-year (YoY).
Inquire for Discount on the Report at http://www.rnrmarketresearch.com/contacts/discount?rname=753899
Further, the report states that one major challenge in the market is discontinuation of drugs under development leading to substantial loss of revenue. Discontinuation of the drugs under development or from the market after its launch due to non-satisfactory safety or efficacy result is a major challenge for the market. Discontinuation in the late stages of development or from the market will lead to a heavy loss in revenues because of the high R&D and marketing costs invested by the company.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.